miR-107 and miR-29b target the β-site APP cleaving enzyme BACE1, whose proteolytic activity generates amyloid β polypeptide, the primary component of amyloid plaques found in the brains of AD patients (Blennow et al., 2006; Hébert et al., 2008; Nelson and Wang, 2010; O’Brien and Wong, 2011; Zhang et al., 2011; Takahashi et al., 2017). The gene discussed is BACE1; the disease is Alzheimer disease.